多西他赛联合顺铂和5-氟脲嘧啶治疗转移性食管癌的临床研究  

Clinical Study of Docetaxel Combined with Cisplatin and 5-Fu in the Treatment of Patients with Metastatic Esophageal Cancer

作　　者：任庆[1] 伍靖武[1] 熊锐华[1] 周欣[1] 

机构地区：[1]解放军第181医院肿瘤治疗中心,广西桂林541002

出　　处：《肿瘤基础与临床》2009年第6期489-491,共3页journal of basic and clinical oncology

摘　　要：目的观察多西他赛联合顺铂和5-氟脲嘧啶方案治疗转移性食管癌的近期疗效和毒副反应。方法经病理学确诊的36例转移性食管癌接受多西他赛联合顺铂和5-氟脲嘧啶方案化疗，多西他赛75mg／m^2，静脉滴注，d1；顺铂80mg／m^2，静脉滴注，d1；5-氟脲嘧啶500mg／m^2，静脉滴注，d1-5；2Id为1周期，治疗4～6周期后评价疗效及毒剐反应。结果全组病例均可评价疗效，其中CR2例，PR18例，有效率为55．56％；主要的毒副反应为骨髓抑制，非血液学毒性较轻；无治疗相关死亡病例。结论多西他赛联合顺铂和5-氟脲嘧啶方案治疗转移性食管癌疗效较好，毒副反应町耐受。Objective To evaluate the recent efficacy and toxicity of docetaxel combined with cisplatin and 5-Fu in the treatment of patients with metastatic esophageal cancer. Methods 36 patients with metastatic esophageal cancer received docetaxel combined with cisplatin and 5-Fu chemotherapy regimen, docetaxel was given in the dosage of 75 mg/m^2 on day 1, cisplatin was given in the dosage of 80 mg/m^2 on day 1, 5-Fu 500 mg/m^2 on days 1-5; 21 days was 1 cycle; the efficacy and toxicity were evaluated after 4-6 cycles. Results All the patients were assessable for efficacy, CR 2 cases, PR 18 cases, the response rate was 55.56% ; the main toxicity was myelosuppression, non-hematologic toxicity was light. There was no death during the treatment. Conclusion The efficacy of docetaxel combined with cisplatin and 5-Fu in the treatment of patients with metastatic esophageal cancer is better,and its toxicities can be tolerated.

关 键 词：转移性食管癌 多西他赛 联合化疗 

分 类 号：R730.53[医药卫生—肿瘤] R735.1[医药卫生—临床医学]